TARDBP and Alzheimer disease: The increased capability of MAb No. 9 to reveal more TDP-43 pathology immunohistochemically in FTLD-TDP type A and type B, and AD with LATE-NC tissues compared to MAb 409/410 may be attributed to the higher affinity of MAb No. 9.